-
Science's next-generation single-molecule protein sequencing technology marks a new era in life sciences and biomedical research
Time of Update: 2022-10-20
Quantum-Si is a life sciences company commercializing the first next-generation single-molecule protein sequencing platform. Today, the company published a new study in the academic journal Science,
-
The new generation of the world's "best-selling" small molecule drug controversy has not been
Time of Update: 2022-09-09
In Barcelona, Spain, the 2022 European Annual Conference on Cardiology is being held, and at this large-scale four-day academic event, two reports have received much expectation and attention from ma
-
Ruige Pharmaceutical's new generation of CDK2/4/6 small molecule inhibitors received clinical approval in the U.S.
Time of Update: 2022-01-09
The clinical development project of RGT-419B will solve this resistance to CDK4/6 and other hormone receptor modulating therapies, and provide new opportunities for improving the survival and quality of life of patients with advanced breast cancer .
-
Targeting difficult-to-drug targets US$50 million to help develop next-generation small molecule discovery platforms
Time of Update: 2021-09-13
Jnana's pilot project aims to reduce the level of Phe in the blood that drives the pathology of PKU disease by inhibiting SLC6A19, so as to provide a new oral small molecule therapy for the treatment of PKU .
Retrieved August 18, 2021, from https:// therapeutics-closes-50-million-series-b-financing-to-advance-lead-pku-program-and-small-molecule-pipeline-based-on-next-gen-chemoproteomic-platform/
-
Fuwo Pharmaceutical's fourth-generation EGFR small molecule targeted drug was approved for clinical use in China
Time of Update: 2021-06-16
According to the latest announcement from the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China, the fourth-generation EGFR small molecule targeted drug FWD1509 independently developed by Fuwo Pharmaceutical has been approved for clinical use in China, and its indication is advanced non-small cell lung cancer ( NSCLC) .
-
Not willing to lag behind, Sanofi is a new generation of oral small molecule tumor immunotherapy
Time of Update: 2015-08-11
Source: Biovalley, August 11, 2015, tumor immunotherapy is a new treatment method in the field of tumor therapy It can resist cancer by enhancing the immune function of human body, and the most remark